Literature DB >> 6187828

Epitopes associated with a synthetic hepatitis B surface antigen peptide.

I Ionescu-Matiu, R C Kennedy, J T Sparrow, A R Culwell, Y Sanchez, J L Melnick, G R Dreesman.   

Abstract

A synthetic peptide (SP1), corresponding to the amino acid residues 122 through 137 of the major polypeptide derived from hepatitis B surface antigen (HBsAg), subtype ayw, was analyzed for the presence of the major epitopes of HBsAg. Both a cyclic form, produced by introduction of an intrachain disulfide bond, and a linear form of the peptide were characterized. A panel of monoclonal antibodies with defined specificity for the cross-reactive group a antigenic determinant(s) and for the y and w subtype specificities was used for this analysis. The cyclic, but not the linear, form of SP1 reacted with five of 14 anti-a monoclonal antibodies, demonstrating that the cyclic peptide contains a conformation-dependent a epitope. Only one anti-a antibody was found to react with both cyclic and linear forms of SP1. Because SP1 failed to react with the remaining 8 anti-a monoclonal antibodies, it was concluded that the a antigenic reactivity associated with HBsAg contains an additional epitope(s) unrelated to that expressed on SP1. Both cyclic and linear SP1 reacted with three of three anti-y monoclonal antibodies, indicating that a sequential y epitope is also present on SP1; no w reactivity was detected. Analysis of the idiotypes associated with the monoclonal antibodies showed those that combined with cyclic SP1 also inhibited the binding of a common human anti-HBs (CHBs) idiotype with its rabbit anti-idiotype serum, whereas a monoclonal antibody that did not react with the cyclic SP1 epitope failed to inhibit the CHBs idiotype-anti-idiotype reaction. Thus, the conformational a epitope present on cyclic SP1 appears to contain the predominant epitope recognized by humans in response to a natural HBV infection.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6187828

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Antibody responses to recombinant and plasma derived hepatitis B vaccines.

Authors:  S E Brown; C Stanley; C R Howard; A J Zuckerman; M W Steward
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-18

2.  Seventh International Conference on Methods in Protein Sequence Analysis. July 3-8, 1988, West Berlin, F.R.G. Short communications.

Authors: 
Journal:  J Protein Chem       Date:  1988-06

3.  Immunogenicity of a Yersinia pestis vaccine antigen monomerized by circular permutation.

Authors:  David A Chalton; Julie A Musson; Helen Flick-Smith; Nicola Walker; Alistair McGregor; Heather K Lamb; E Diane Williamson; Julie Miller; John H Robinson; Jeremy H Lakey
Journal:  Infect Immun       Date:  2006-09-18       Impact factor: 3.441

4.  Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccine.

Authors:  Delia F Tifrea; Guifeng Sun; Sukumar Pal; Gustavo Zardeneta; Melanie J Cocco; Jean-Luc Popot; Luis M de la Maza
Journal:  Vaccine       Date:  2011-05-06       Impact factor: 3.641

5.  Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum.

Authors:  Delia F Tifrea; Sukumar Pal; Jean-Luc Popot; Melanie J Cocco; Luis M de la Maza
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

6.  Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein.

Authors:  Guifeng Sun; Sukumar Pal; Joseph Weiland; Ellena M Peterson; Luis M de la Maza
Journal:  Vaccine       Date:  2009-05-27       Impact factor: 3.641

7.  Protection of chimpanzees from type B hepatitis by immunization with woodchuck hepatitis virus surface antigen.

Authors:  P J Cote; M Shapiro; R E Engle; H Popper; R H Purcell; J L Gerin
Journal:  J Virol       Date:  1986-12       Impact factor: 5.103

8.  Hepatitis B viral antigenic structure: signature analysis by monoclonal radioimmunoassays.

Authors:  J R Wands; M A Wong; J Shorey; R D Brown; R A Marciniak; K J Isselbacher
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

9.  Identification of immunodominant antigens of Chlamydia trachomatis using proteome microarrays.

Authors:  Douglas M Molina; Sukumar Pal; Mathew A Kayala; Andy Teng; Paul J Kim; Pierre Baldi; Philip L Felgner; Xiaowu Liang; Luis M de la Maza
Journal:  Vaccine       Date:  2009-12-29       Impact factor: 3.641

10.  Molecular mimicry of hepatitis B surface antigen by an anti-idiotype-derived synthetic peptide.

Authors:  M W Pride; H Shi; J M Anchin; D S Linthicum; P T LoVerde; A Thakur; Y Thanavala
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.